Shares of biopharmaceutical company Gilead Sciences continue to climb despite market turbulence. Since the beginning of 2020, shares gained more than 14%. According to World Health Organization (WHO), Gilead Sciences became the first biopharmaceutical company, which could develop a drug treatment to fight COVID-19.
Gilead Sciences is a biopharmaceutical company focused on research, development, and commercialization of innovative medicines to improve care of patients suffering from life-threatening diseases. The company mostly focuses on treatments to HIV, AIDS, liver disease, and severe cardiovascular and respiratory diseases, which includes Coronavirus.
The company is known mainly for HIV treatment from 1990, when Michael L. Riordan and Erik De Clerq was accompanied by scientist Antonin Holy. The three of them were referred to as “The Holy Trinity”. Antonín Holy played an important role in creating drugs to treat HIV and Hepatitis B.
After 5 years of its existence, Gilead Sciences entered NASDAQ. Back then, the company already cooperated with Mr. Holy. His drugs were and still are among the most successful and best-earning drugs ever sold by Gilead Sciences.
The company’s current success is permission to use its experimental drug treatment of Coronavirus. The U.S. allowed procedure, which enables emergency treatment with nonapproved drugs.
Gilead Sciences keeps developing treatment for HIV and is further progressing towards drug application to enhance immune function of a patient, which leads to viral remission and reduces patient’s reactions in the absence of antiretroviral therapy.
Since the beginning of 2020, shares of the company gained more than 14%. The main reason is drug treatment to fight COVID-19. Yet, similarly to other companies, Gilead Sciences has experienced decline due to investment spillovers in last two days. Unfortunately, investors tend to invest to less risky assets.
Main representatives of Gilead Sciences announced that HIV treatment remains the ultimate long-term goal for research and development efforts of the biopharmaceutical company.
Milosh Pham, Chief Analyst, Alpho